Start / Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation / 162 how to achieve 85 cell recovery without dmsos toxic side effects with jeffrey allen part 2

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2

16 min • 12 juni 2025

The world of cell therapy is changing rapidly, with revolutionary advancements in cryopreservation and bioprocessing protocols leading the way. In a recent episode of the Smart Biotech Scientist Podcast, host David Brühlmann sat down with Jeffrey Allen, Chairman and CEO of Evia Bio, to dive deep into the “how” of implementing cutting-edge techniques in the lab and the strategic mindset needed to move therapies from concept to clinic successfully.

Jeffrey Allen is a passionate leader with a diverse background in shaping strategy, building high-performing teams, and driving exceptional results across public and private equity-backed organizations. With extensive C-level and international experience in the life sciences sector, Jeffrey has a proven track record of transforming performance and delivering profitable growth in various market environments.

Here are three key takeaways for anyone passionate about advancing biotech:

The four-step audit: bridging best practices and real-world results: Depending on client needs, the audit is performed either at the client’s laboratory or at Evia Bio’s own facility, ensuring real-world practices are scrutinized and optimized.
Protocols matter and so does execution: Even the best-written protocols can falter if not followed meticulously. Regular process audits, sometimes conducted onsite by external partners, help identify “protocol creep” and ensure teams are consistently implementing best practices.
Culture fuels innovation: Jeffrey’s leadership advice resonated-aligning on strategy, fostering unified company culture, and surrounding yourself with talented people accelerates growth. Passion for the mission, combined with a strong, diverse team, can deliver both exceptional results and lasting employee engagement.

Curious how these insights could save you months of frustration and millions in development costs? Tune in to the full episode, or get in touch to discuss how process optimization can empower your cell therapy journey!

Connect with Jeffrey Allen:

LinkedIn: www.linkedin.com/in/jeffreydallen2

Website: www.eviabio.com

Email: jeffrey.allen@eviabio.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

Senaste avsnitt

172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2

17 juli | 20 min

171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1

15 juli | 21 min

170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

10 juli | 23 min

169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1

8 juli | 26 min

168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2

3 juli | 25 min

162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2

Senaste avsnitt

172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2

171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1

170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1

168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2

167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1

166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 2

165: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 1

164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 2

163: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 1

162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2

161: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 1

160: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 2

159: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 1

158: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 2

157: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 1

156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook

155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything

154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 2

153: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 1

152: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 2

151: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 1

150: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 2

149: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 1

148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 2

147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1

146: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 2

145: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 1

144: The Future of Biotech: Making Biotherapeutics More Accessible Faster

143: Bioprocess Breakthroughs: How Smart Bioprocessing Is Democratizing Life-Saving Treatments

142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 2

141: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 1

140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 2

139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1

138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2

137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1

136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)

135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All

134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2

133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1

132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 2

131: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 1

130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2

129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1

128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2

127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1

126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2

125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1

124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2

123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1

122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2

121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1

120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2

119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1

118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 2

117: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 1

116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2

115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1

114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2

113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1

112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2

111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1

110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2

109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1

108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2

107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1

106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2

105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1

104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2

103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1

102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2

101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1

100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2

99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1

98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2

97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1

96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2

95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1